

## **Edwards Is Enough!**

Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia

Meeting Name

#### **Disclosure Statement of Financial Interest**

Within the past 12 months, I or my spouse/partner have had a financial Interest /arrangement or affiliation with the organization(s) listed below

Affiliation/Financial Relationship Grant/ Research Support:

**Consulting Fees/Honoraria:** 

Major Stock Shareholder/Equity Interest:

**Royalty Income:** 

**Ownership/Founder:** 

Salary:

**Intellectual Property Rights:** 

**Other Financial Benefit:** 

<u>Company</u> Medtronic Inc

Edwards Lifesciences (consultant & proctor) My title is "Edwards is enough!!"

• Or is it "Edwars is better than CoreValve"...?

What is "enough"??

- True percutaneous insertion
- No need for general anesthesia
- Multiple valve sizes
- An easy sizing tool for annular size
- Smallest size possible <16 Fr</p>
- Smooth outer surface to pass through aorta
- Easy transition over arch
- Easy transit through valve
- "Self seating"
- Adequate radial strength
- Repositionable if needed
- Retrievable if needed
- No valve gradient
- Conforms to annulus without AR
- Long term durability

#### True percutaneous insertion

- No need for general anesthesia
- Multiple valve sizes
- An easy sizing tool for annular size
- Smallest size possible <16 Fr</p>
- Smooth outer surface to pass through aorta
- Easy transition over arch
- Easy transit through valve
- "Self seating"
- Adequate radial strength
- Repositionable if needed
- Retrievable if needed
- No valve gradient
- Conforms to annulus without AR
- Long term durability

#### **Percutaneous Aortic Valve Replacement**

Vascular Outcomes With a Fully Percutaneous Procedure

Stefan Toggweiler, MD,\* Ronen Gurvitch, MBBS,\* Jonathon Leipsic, MD,† David A. Wood, MD,\* Alexander B. Willson, MBBS,\* Ronald K. Binder, MD,\* Anson Cheung, MD,‡ Jian Ye, MD,‡ John G. Webb, MD\*

Vancouver, British Columbia, Canada

ResultsPAVR was performed in 137 consecutive patients. All but 1 patient underwent planned arteriotomy closure using a<br/>percutaneous pre-closure technique. Smaller sheaths, rigorous angiographic and computed tomographic screening<br/>and patient selection, and percutaneous vascular repair techniques were increasingly used over this period. From<br/>2009 to 2010, major vascular complications decreased from 8% to 1% (p = 0.06), minor vascular complications<br/>decreased from 24% to 8% (p < 0.01), major bleeds fell from 14% to 1% (p < 0.01), and unplanned surgery de-<br/>creased from 28% to 2% (p < 0.01). A minimal artery diameter smaller than the external sheath diameter, moderate<br/>or severe calcification, and peripheral vascular disease were associated with higher vascular complication rates.

True percutaneous insertion

#### No need for general anesthesia

- Multiple valve sizes
- An easy sizing tool for annular size
- Smallest size possible <16 Fr</p>
- Smooth outer surface to pass through aorta
- Easy transition over arch
- Easy transit through valve
- "Self seating"
- Adequate radial strength
- Repositionable if needed
- Retrievable if needed
- No valve gradient
- Conforms to annulus without AR
- Long term durability

~~





Transcatheter Valve Therapies (TVT)



- True percutaneous insertion
- No need for general anesthesia

#### Multiple valve sizes

- An easy sizing tool for annular size
- Smallest size possible <16 Fr</p>
- Smooth outer surface to pass through aorta
- Easy transition over arch
- Easy transit through valve
- "Self seating"
- Adequate radial strength
- Repositionable if needed
- Retrievable if needed
- No valve gradient
- Conforms to annulus without AR
- Long term durability

~ ~ ~ ~

### Edwards NovaFlex+ 29mm TF : Q2, 2012 CE Mark

• SAPIEN XT valves with dimensions and associated annulus size ranges





- True percutaneous insertion
- No need for general anesthesia
- Multiple valve sizes

### An easy sizing tool for annular size

- Smallest size possible <16 Fr</p>
- Smooth outer surface to pass through aorta
- Easy transition over arch
- Easy transit through valve
- "Self seating"
- Adequate radial strength
- Repositionable if needed
- Retrievable if needed
- No valve gradient
- Conforms to annulus without AR
- Long term durability

## **Aortic Annulus Measurement**



TOE:

- -Long Axis view
- -See valve leaflets
- -See the leaflet insertion / hinge



## **MSCT** Assessment of Annulus



Figure 2 Three-Dimensional MDCT Aortic Annular Measurements

(A) Short and long diameters provide a mean annulus diameter and annular eccentricity. (B) Annular area. (C) Annular circumference. MDCT = multidetector computed tomography.

- Mean Diameter as Average of Smallest & Largest Diameters
- Mean Diameter as Annular Circumference / π
- Mean Diameter as  $\sqrt{(4x \text{ Annular Area } / \pi)}$
- Annular Area
- Annular Circumference

Willson et al, JACC 2012



Willson et al, JACC 2012

11

- True percutaneous insertion
- No need for general anesthesia
- Multiple valve sizes
- An easy sizing tool for annular size

### Smallest size possible <16 Fr</p>

- Smooth outer surface to pass through aorta
- Easy transition over arch
- Easy transit through valve
- "Self seating"
- Adequate radial strength
- Repositionable if needed
- Retrievable if needed
- No valve gradient
- Conforms to annulus without AR
- Long term durability

## The Edwards eSheath - 16Fr



The eSheath expands from 16F to 18F which facilitates smooth delivery system passage, then returns to a reduced profile once the valve has passed through the sheath



## Upcoming Development – 14Fr!

### Edwards **SAPIEN 3** Valve





- Lower profile valve delivered through a14 Fr eSheath
- Discrete valve that anchors in the annulus
- Treated bovine pericardial tissue lleaflets
- Delivered through 14-French eSheath delivery systems

11

11

- True percutaneous insertion
- No need for general anesthesia
- Multiple valve sizes
- An easy sizing tool for annular size
- Smallest size possible <16 Fr</p>
- Smooth outer surface to pass through aorta
- Easy transition over arch
- Easy transit through valve
- "Self seating"
- Adequate radial strength
- Repositionable if needed
- Retrievable if needed
- No valve gradient
- Conforms to annulus without AR
- Long term durability

## Crossing Arch and Native Aortic Valve with RetroFlex / NovaFlex Catheter





## NovaFlex to Cross Unfolded Aorta Maximal Flexion and Tension on Wire



- True percutaneous insertion
- No need for general anesthesia
- Multiple valve sizes
- An easy sizing tool for annular size
- Smallest size possible <16 Fr</p>
- Smooth outer surface to pass through aorta
- Easy transition over arch
- Easy transit through valve
- "Self seating"
- Adequate radial strength
- Repositionable if needed
- Retrievable if needed
- No valve gradient
- Conforms to annulus without AR
- Long term durability



#### NovaFlex System – Easier to achieve co-axial alignment - Does no move much during valve deployment



## Valve-in-valve Rescue

■ SOURCE (Edwards) – 1.4%

■ ADVANCE (CoreValve) – 4%

- True percutaneous insertion
- No need for general anesthesia
- Multiple valve sizes
- An easy sizing tool for annular size
- Smallest size possible <16 Fr</p>
- Smooth outer surface to pass through aorta
- Easy transition over arch
- Easy transit through valve
- "Self seating"
  - But ease of deployment improved + +
- Adequate radial strength
- Repositionable if needed
- Retrievable if needed
- No valve gradient
- Conforms to annulus without AR
- Long term durability



- True percutaneous insertion
- No need for general anesthesia
- Multiple valve sizes
- An easy sizing tool for annular size
- Smallest size possible <16 Fr</p>
- Smooth outer surface to pass through aorta
- Easy transition over arch
- Easy transit through valve
- "Self seating"

#### Adequate radial strength

- Repositionable if needed
- Retrievable if needed
- No valve gradient
- Conforms to annulus without AR
- Long term durability



### Geometry of Edwards SAPIEN Post-implant



- □ Circularity (Min D / Max D >0.9) 98%
- Average Expansion 104%

### Geometry of CoreValve Post-implant



#### Circularity (Min D / Max D >0.9)

- 0% at ventricular end
- 17% at leaflet nadie and central co-aptation
- None reach nominal diameter

- True percutaneous insertion
- No need for general anesthesia
- Multiple valve sizes
- An easy sizing tool for annular size
- Smallest size possible <16 Fr</p>
- Smooth outer surface to pass through aorta
- Easy transition over arch
- Easy transit through valve
- "Self seating"
- Adequate radial strength
- Repositionable if needed
- Retrievable if needed
- No valve gradient
- Conforms to annulus without AR
- Long term durability



- True percutaneous insertion
- No need for general anesthesia
- Multiple valve sizes
- An easy sizing tool for annular size
- Smallest size possible <16 Fr</p>
- Smooth outer surface to pass through aorta
- Easy transition over arch
- Easy transit through valve
- "Self seating"
- Adequate radial strength
- Repositionable if needed
- Retrievable if needed
- No valve gradient
- Conforms to annulus without AR
- Long term durability

11 11 Х X

**True percutaneous insertion** No need for general anesthesia **Multiple valve sizes** An easy sizing tool for annular size Smallest size possible <16 Fr Smooth outer surface to pass through aorta Easy transition over arch Easy transit through valve "Self seating" Adequate radial strength **Repositionable if needed Retrievable if needed** No valve gradient **Conforms to annulus without AR** Long term durability 

11 11 Х X

## PARTNER Cohort A Sustained Haemodynamic Improvement



Kodali, NEJM 2012

11

11

Х

X

**True percutaneous insertion** No need for general anesthesia Multiple valve sizes An easy sizing tool for annular size Smallest size possible <16 Fr Smooth outer surface to pass through aorta Easy transition over arch Easy transit through valve "Self seating" Adequate radial strength **Repositionable if needed Retrievable if needed** No valve gradient **Conforms to annulus without AR** Long term durability 

### PARTNER COHORT A - Aortic Regurgitation (As Treated)



# **Aortic Regurgitation**

| Hospital San      | All TF    | SAPIEN TF | CoreValve | р    |
|-------------------|-----------|-----------|-----------|------|
| Raffaele          | (n = 245) | (n= 155)  | (n = 90)  |      |
| AR 3 or 4+; N (%) | 12 (4.9%) | 6 (3.9%)  | 6 (6.7%)  | .328 |

11

11

Х

X

X

**True percutaneous insertion** No need for general anesthesia Multiple valve sizes An easy sizing tool for annular size Smallest size possible <16 Fr Smooth outer surface to pass through aorta Easy transition over arch Easy transit through valve "Self seating" Adequate radial strength **Repositionable if needed Retrievable if needed** No valve gradient Conforms to annulus without AR Long term durability 

#### Transcatheter Aortic Valve Implantation Durability of Clinical and Hemodynamic Outcomes Beyond 3 Years in a Large Patient Cohort

R. Gurvitch, MBBS; D.A. Wood, MD; E.L. Tay, MBBS; J. Leipsic, MD; J. Ye, MD;
S.V. Lichtenstein, MD, PhD; C.R. Thompson, MD; R.G. Carere, MD; N. Wijesinghe, MD;
F. Nietlispach, MD; R.H. Boone, MD; S. Lauck, RN; A. Cheung, MD; J.G. Webb, MD

- 70 patients who had Edwards SAPIEN valve implant with at least 3 year follow-up
- Median F/up 3.7 years
- Mean gradient increased from 10.0mmHg to 12.7mmHg (p=0.03)
- No structural deterioration or stent fracture

**True percutaneous insertion** 11 No need for general anesthesia Multiple valve sizes An easy sizing tool for annular size 11 Smallest size possible <16 Fr Smooth outer surface to pass through aorta Easy transition over arch Easy transit through valve "Self seating" Adequate radial strength **Repositionable if needed** Х X **Retrievable if needed** No valve gradient Conforms to annulus without AR X Long term durability ?? 

## TAVI – Contemporary Results

|                       | PARTNER<br>B   | PARTNER<br>A   | SOURCE          | Canadian       | FRANCE<br>2                         | CoreValve<br>Meta-<br>analysis | ADVANC<br>E       |
|-----------------------|----------------|----------------|-----------------|----------------|-------------------------------------|--------------------------------|-------------------|
| N & Valve<br>type     | Edwards<br>179 | Edwards<br>348 | Edwards<br>2307 | Edwards<br>339 | Edwards<br>1145<br>CoreValve<br>540 | CoreValve<br>2156              | CoreValve<br>1015 |
| Age                   | 83.1           | 83.6           | 80.1            | 81.8           | 82.5                                | 81.6                           | 81                |
| Logistic<br>EuroScore | 26.4%          | 29.3%          | 26.1%           | N/A            | 22.6%                               | 21.3%                          | 19.2%             |
| 30 day<br>Mortality   | 5.0%           | 3.4%           | 9.5%            | 10.4%          | 9.9%                                | 6.6%                           | 4.5%              |
| 30 day<br>Stroke      | 6.7%           | 5.5%           | 2.9%            | 2.3%           | 3.8%                                | 2.8%                           | 2.9%              |
| 1 year<br>Mortality   | 30.7%          | 24.2%          | 23.5%           | 24%            | 24%                                 | 17.1%                          |                   |

## TAVI – Contemporary Results

|                   | PARTNE<br>R B  | PARTNE<br>R A  | <b>SOURCE</b><br>1 & 2 | Canadian       | FRANCE<br>2                         | CoreValve<br>Meta-<br>analysis | ADVANC<br>E       |  |
|-------------------|----------------|----------------|------------------------|----------------|-------------------------------------|--------------------------------|-------------------|--|
| N &<br>Valve type | Edwards<br>179 | Edwards<br>348 | Edwards<br>2307        | Edwards<br>339 | Edwards<br>1145<br>CoreValve<br>540 | CoreValve<br>2156              | CoreValve<br>1015 |  |
| Vascular<br>Cx    | 16.8%          | 11.0%          | 5.7%                   | 13.0%          | 12.5%                               | 4.2%                           | 10.7%             |  |
| Bleeding          | 16.2%          | 9.3%           | 3.3%                   | N/A            | 18.4%                               | N/A                            | 13.7%             |  |
| PPM               | 3.4%           | 3.8%           | 6.9%                   | 4.9%           | 12.4%                               | 28.7%                          | 26.7%             |  |

## Conclusion

Is Edwards balloon expandable valve enoughProbably not

Is Edwards better than CoreValveYes in terms of PPM

# What is Enough??

- True percutaneous insertion
- No need for general anesthesia
- Multiple valve sizes
- An easy sizing tool for annular size
- Smallest size possible <16 Fr</p>
- Smooth outer surface to pass through aorta
- Easy transition over arch
- Easy transit through valve
- "Self seating"
- Adequate radial strength
- Repositionable if needed
- Retrievable if needed
- No valve gradient
- Conforms to annulus without AR
- Long term durability

Same day admit Local anesthesia Versed/fentanyl Radial/fem insertion (7Fr) 4 hr recovery Home -----